Lupin unveils generic equivalent of Perforomist Inhalation Solution in US
Mumbai: Global pharma major Lupin Limited today announced the launch of Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial in United States.
The product is a generic equivalent of Perforomist Inhalation Solution, 20 mcg/2 mL, of Mylan Specialty, L.P.
PERFOROMIST Inhalation Solution is a long-acting beta2-adrenergic agonist (beta2-agonist) indicated for:
ï‚· Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of USD 268 million in the U.S. (IQVIA MAT September 2022).
Read also: Lupin arm acquires right to Limbitrol, Bacrocin and 7 other medicines from Bausch Health
Medical Dialogues team had earlier reported that Lupin Human Welfare and Research Foundation (LHWRF), the Corporate Social Responsibility (CSR) arm of Lupin Limited, had signed a Memorandum of Understanding (MoU) with the Government of Rajasthan to address the prevalence of Cardiovascular Disease (CVD) and Chronic Obstructive Pulmonary Disease (COPD) in the Alwar district of Rajasthan.
Read also: Lupin CSR arm, Rajasthan Govt join hands to strengthen Healthcare system
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health areas. The company invested 8.7% of its revenue in research and development in FY22.
Read also: Lupin CSR arm, Rajasthan Govt join hands to strengthen Healthcare system
